S/N: 09/742,892 Docket: ARK-P001 (formely GDI-2)

- (UN-AMENDED) The vaccine of claim 4, wherein said recombinant viral vector is selected from the group consisting of adenovirus, adeno-associated virus, herpes virus, vaccinia and RNA viruses.
- 6. (UN-AMENDED) The vaccine of claim 5, wherein said recombinant viral vector is an adenovirus.
- (UN-AMENDED) The vaccine of claim 1, wherein said vector further comprises a
 nucleotide sequence encoding an adjuvant.
- 8. (UN-AMENDED) The vaccine of claim 7, wherein said adjuvant is a cytokine.
- 9. (UN-AMENDED) The vaccine of claim 8, wherein said cytokine is IL-2, IL-12, or both.
- 10. (UN-AMENDED) The vaccine of claim 1, wherein said antigen is a lipase gene or fragments thereof, a hyaluronidase gene or fragments thereof, a phosphatase gene or fragments thereof, or combinations of the foregoing.
- 11. (AMENDED) A method of treating or preventing a disease caused by a pathogen capable of infecting, or avoiding destruction by, macrophages, said method comprising obtaining a vaccine comprising at least one vector that comprises at least one nucleotide sequence encoding at least one antigen derived from said pathogen; and administering said vaccine to a recipient in need thereof; wherein the vaccine comprises a genetic vaccine utilizing a recombinant vector or modified polypeptides, the vaccine further comprising antigens that do not cause a destructive form of acne.
- 12. **(UN-AMENDED)** The method of claim 11, wherein said administering comprises routes of administration comprising oral, intravenous, intramuscular, transcutaneous, subcutaneous, aerosol, ocular, rectal, intraperitoneal, intrathecal, or combinations thereof.
- (UN-AMENDED) The method of claim 12, wherein administering comprises transcutaneous administration.

N. 6.

AV 15

10

N. É

20

S/N: 09/742,892 Docket: ARK-P001 (formely GDI-2)

- 14. **(UN-AMENDED)** The method of claim 13, wherein said transcutaneous administration comprises applying said at least one vector to a patch, and adhering said patch to skin of said recipient.
- 15. (UN-AMENDED) The method of claim 11, wherein said pathogen is P. acnes, L. monocytogenes, S. typhimurium, N. gonorrhoea, M. avium, M. tuberculosis, M. leprae, B. abortus, C. albicans; L. major, or combinations thereof.
- 16. (UN-AMENDED) The method of claim 15, wherein said pathogen is *P. acnes*.
- 17. **(UN-AMENDED)** The method of claim 11, wherein said at least one vector comprises naked DNA, a recombinant viral vector, or a combination of both.
- 18. **(UN-AMENDED)** The method of claim 17, wherein said recombinant viral vector is an adenovirus.
 - 19. (UN-AMENDED) A kit comprising a container and one or more patches, wherein said patches have disposed thereon at least one vector comprising a nucleotide sequence encoding an antigen derived from a pathogen, said pathogen being capable of infecting, or avoiding destruction by, macrophages.
 - 20. (AMENDED) An article of manufacture comprising a vaccine solution disposed within a tube, vial, bottle, can, or syringe, wherein said vaccine solution comprises a viral vector comprising a nucleotide sequence encoding an antigen derived from a pathogen, said pathogen being capable of infecting, or avoiding destruction by, macrophages; wherein the vaccine solution comprises a genetic vaccine utilizing a recombinant vector or modified polypeptides, the vaccine further comprising antigens that do not cause a destructive form of acne.
 - 21. (UN-AMENDED) The vaccine of claim 1, wherein said vaccine is in the form of an aqueous solution.
 - 22. **(UN-AMENDED)** The vaccine of claim 1, wherein said vaccine further comprises a nucleotide sequence encoding a co-stimulatory molecule.

Miks.

5

10

15

A3

20

N' 25

S/N: 09/742,892 Docket: ARK-P001 (formely GDI-2)

机火

23. (UN-AMENDED) The vaccine of claim 22, wherein said co-stimulatory molecule comprises a B7 protein, a CD40 protein or both.

A M 5

24. (AMENDED) A method of cosmetically improving the appearance of a person's skin who is suffering from acnes vulgaris, said method comprising the steps of obtaining a composition comprising a mixture of at least one vector that comprises at least one nucleotide sequence encoding at least one antigen derived from P. acnes, and a cosmetic agent; and administering said composition to said person; wherein the composition comprises a genetic vaccine utilizing a recombinant vector or modified polypeptides, the vaccine further comprising antigens that do not cause a destructive form of acne.

15

10

20